Aprepitant and Lemborexant interaction
Aprepitant and Lemborexant: the Lemborexant prescribing label flags this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Lemborexant (DAYVIGO) label · effective 2025-02-24
Strong or moderate CYP3A inhibitors: Avoid concomitant use.
Strong or moderate CYP3A inducers: Avoid concomitant use.
Intervention: Avoid concomitant use of DAYVIGO with strong or moderate CYP3A inhibitors [see Dosage and Administration ( 2.2 )].
Intervention: Avoid concomitant use of DAYVIGO with strong or moderate CYP3A inducers [see Dosage and Administration ( 2.2 )].
Weak CYP3A inhibitors: The maximum recommended dose is 5 mg.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.